This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform And A Rapidly Ageing Population Provide Strong Stimulus For Growth

Table of Contents

1 Table of Contents 51.1 List of Tables 61.2 List of Figures 72 China Pharmaceutical Market Outlook – Introduction 83 China Pharmaceutical Market Outlook – Macroeconomic Analysis 93.1 General Economics 93.1.1 Gross Domestic Product 93.1.2 Inflation 113.1.3 Exchange Rate 123.1.4 Trade Balance 133.1.5 Foreign Direct Investment 173.2 Demographic 183.2.1 Population Size 183.2.2 Population Distribution 203.3 Health and Healthcare 223.3.1 Healthcare Expenditure 223.3.2 Public and Private Expenditure 253.3.3 Healthcare Facilities 273.3.4 Immunization 293.3.5 Smoking and Alcohol Use Prevalence 303.3.6 Obesity 323.3.7 Life Expectancy 333.3.8 Leading Causes of Death 344 China Pharmaceutical Market Outlook – Market Segments 354.1 Branded and Generic Drugs 354.2 Over-the-Counter and Prescription Drugs 394.3 Biopharmaceuticals 425 China Pharmaceutical Market Outlook – Industry Characteristics 445.1 Pricing Policy 445.2 Regulatory Landscape 455.2.1 Drug Manufacturing Regulations 465.2.2 New Drug Approval 465.2.3 Intellectual Property Protection 475.2.4 Advertising 475.3 Healthcare Overview 485.3.1 Healthcare Reform 485.3.2 Insurance and Reimbursement 495.4 Pharmaceutical Supply Chain 506 China Pharmaceutical Market Outlook – Competitive Landscape 516.1 Domestic Companies in China 516.1.1 Sinopharm 516.1.2 Shanghai Pharmaceutical 526.1.3 Jointown Pharmaceutical 526.1.4 Nanjing Pharmaceutical 536.1.5 Harbin Pharmaceutical 536.2 Macroscopic Domestic Deals Overview 546.3 Foreign Companies in China 567 China Pharmaceutical Market Outlook – Market Drivers and Barriers 577.1 Drivers 577.1.1 Increasing Overweight and Obese Population 577.1.2 High Smoking Prevalence 577.1.3 Aging Population 587.1.4 Government Financial Support 587.1.5 Healthcare Reforms 587.1.6 Increasing Urbanization 597.2 Barriers 597.2.1 Poor Drug Quality 597.2.2 Competition from Neighboring Countries 597.2.3 Popularity of TCM 597.2.4 Increasing Labor Costs 607.2.5 Poor Intellectual Property Protection 608 China Pharmaceutical Market Outlook – Appendix 618.1 Market Definitions 618.2 Abbreviations 618.3 Bibliography 628.4 Research Methodology 648.4.1 Coverage 648.4.2 Secondary Research 648.4.3 Primary Research 648.4.4 Expert Panel Validation 658.5 Contact Us 658.6 Disclaimer 65

List of Tables

Table 1: Leading Causes of Death, China, Deaths per 100,000, 2009 34Table 2: Branded and Generic Drugs, China, Branded/Generic Price Ratio, 2009 37Table 3: OTC Pharmaceuticals, China, Top OTC Product per Class, 2010 41Table 4: OTC Pharmaceuticals, China, Top 10 OTC Pharmaceutical Manufacturers, 2010 41Table 5: Top Multinational Companies, China, Sales ($m) and Share of the Multinational Market (%), 2011 56

List of Figures

Figure 1: Gross Domestic Product, China, Value ($bn) and Annual Growth (%), 2005–2017 9Figure 2: Gross Domestic Product per Capita ($), China, 2005–2017 10Figure 3: Consumer Price Index, China, 2005–2017 11Figure 4: Consumer Price, China, Annual Price Change (%), 2005–2017 11Figure 5: Exchange Rate (USD/CNY), China, 2005–2012 12Figure 6: Import of Goods and Services, China, Value ($bn) and Annual Growth (%), 2005–2017 13Figure 7: Import of Goods, China, Value ($bn) and Annual Growth (%), 2005–2017 13Figure 8: Import of Goods and Services Comparison, China, Value ($bn), 2005–2017 14Figure 9: Export of Goods and Services, China, Value ($bn) and Annual Growth (%), 2005–2017 14Figure 10: Export of Goods, China, Value ($bn) and Annual Growth (%), 2005–2017 15Figure 11: Export of Goods and Services Comparison, China, Value ($bn), 2005–2017 16Figure 12: Trade Balance, China, Value ($bn), 2005–2017 16Figure 13: Foreign Direct Investment, China, Net Investment ($bn), 2005–2011 17Figure 14: Population Size, Three Most Populous Countries, Population (billion), 2005–2017 18Figure 15: Annual Population Growth, China, Percentage (%), 2005–2017 18Figure 16: Crude Birth and Death Rates, China, Rate (Per 1,000 People), 2005–2012 19Figure 17: Population Distribution by Age, China, Percentage (%), 2000–2020 20Figure 18: Population Distribution by Gender, China, Percentage (%), 2011 20Figure 19: Population Distribution by Region, China, Percentage (%), 2005–2015 21Figure 20: Population Size by Region, China, Population (million), 2005–2017 21Figure 21: Healthcare Expenditure (% of GDP), Global, 2010 22Figure 22: Healthcare Expenditure (% of GDP and $bn), China, 2005–2011 23Figure 23: Healthcare Expenditure per Capita ($), China, 2005–2011 23Figure 24: Healthcare Expenditure, China, Rural and Urban Distribution (%), 2009 24Figure 25: Public and Private Healthcare Expenditure, China, Percentage of Total Healthcare Expenditure (%), 2005–2011 25Figure 26: Government Healthcare Expenditure, China, Percentage of Government Expenditure (%), 2005–2011 26Figure 27: Out-of-Pocket Healthcare Expenditure, China, Percentage of Private Healthcare Expenditure (%), 2005–2011 26Figure 28: Healthcare Organizations, China, Distribution (%), 2009 27Figure 29: Urban and Rural Hospitals, China, Distribution (%), 2009 27Figure 30: Hospital Bed Availability, China, Hospital Beds per 1,000 People, 2002–2011 28Figure 31: Physician Availability, China, Physicians per 1,000 People, 2002–2011 28Figure 32: Children Immunized against DPT and Measles, China, Percentage (%), 2002–2011 29Figure 33: Smoking Prevalence, China, Percentage of Population (%), 2009–2010 30Figure 34: Alcohol Use Prevalence, China, Percentage of Population (%), 2010 31Figure 35: Alcohol Use Prevalence, China, Total Pure Alcohol Consumption (billion liters), 2007–2017 31Figure 36: Overweight Population, China, Proportion of Population (%), 2005–2015 32Figure 37: Life Expectancy (Years), China, 2005–2017 33Figure 38: Branded and Generic Drugs, China, Market Share by Hospital, 2010 35Figure 39: Branded and Generic Drugs, China, Revenue Market Share by Therapeutic Category (%), 2010 36Figure 40: Branded and Generic Drugs, China, Sales Quantity Market Share by Therapeutic Category (%), 2010 36Figure 41: Generic Drugs, China, Breakdown by Therapeutic Category (%), 2008 38Figure 42: Pharmaceutical Market, China, Breakdown by Market Segment (%), 2009 39Figure 43: OTC Market, China, Breakdown by Product Type (%), 2011 40Figure 44: Biopharmaceuticals Market, China, Breakdown of Product Types by Sales (%), 2010 42Figure 45: Domestic Deals, China, Types of Deals, 2007–2012 54

Companies Mentioned

SinopharmShanghai PharmaceuticalJointown PharmaceuticalNanjing PharmaceuticalHarbin Pharmaceutical

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs